[go: up one dir, main page]

WO2014027831A1 - Marqueur de pronostic et de diagnostic du cancer de la vessie - Google Patents

Marqueur de pronostic et de diagnostic du cancer de la vessie Download PDF

Info

Publication number
WO2014027831A1
WO2014027831A1 PCT/KR2013/007305 KR2013007305W WO2014027831A1 WO 2014027831 A1 WO2014027831 A1 WO 2014027831A1 KR 2013007305 W KR2013007305 W KR 2013007305W WO 2014027831 A1 WO2014027831 A1 WO 2014027831A1
Authority
WO
WIPO (PCT)
Prior art keywords
bladder cancer
methylation
gene
isl1
hoxa9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2013/007305
Other languages
English (en)
Korean (ko)
Inventor
김용준
김원재
윤형윤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI)
Chungbuk National Univiversity CBNU
Korea Health Industry Development Institute
Original Assignee
KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI)
Chungbuk National Univiversity CBNU
Korea Health Industry Development Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI), Chungbuk National Univiversity CBNU, Korea Health Industry Development Institute filed Critical KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE(KHIDI)
Publication of WO2014027831A1 publication Critical patent/WO2014027831A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders

Definitions

  • the present invention relates to a novel biomarker and its use for the diagnosis of bladder cancer, more specifically non-invasive (superficial) using the expression characteristics according to the methylation pattern of one or more genes selected from the group consisting of HOXA9, ISL1 and ALDH1A3.
  • NMIBC Non-muscle Invasive Bladder Cancer
  • Bladder cancer is the most frequent cancer in the urinary system. It is reported that 16.5 cases per 100,000 population occur in the West and 4.5 cases occur in Korea. Although the incidence rate is lower than in the West, the incidence rate is increasing year by year, and it is known as the most frequent cancer among the urinary system cancers in Korea (Lee C, et al., 1992).
  • Noninvasive bladder cancer is a lesion in which the cancer is confined to the mucous membrane without invasion of the muscle layer, and can be treated relatively simply by transurethral resection of bladder tumor or by injecting an anticancer agent or BCG into the bladder. Progression becomes a problem.
  • Invasive bladder cancer refers to a condition in which the cancer has infiltrated into the muscle layer.
  • complex urinary diversion may be performed, and the patient may have fatal results. Therefore, prediction and early detection and prevention of recurrence and progression after primary treatment are very important.
  • DNA methylation mainly occurs in the cytosine of CpG island of the promoter region of a specific gene, whereby the binding of transcription factors interferes.
  • MSP methylation specific PCR
  • Promoter methylation of tumor-related genes is an important indicator of cancer and can be used in many ways, including the diagnosis and early diagnosis of cancer, the prediction of carcinogenic risk, the prognosis of cancer, the follow-up of treatment, and the prediction of response to anticancer therapy.
  • Attempts have recently been made to investigate the promoter methylation of tumor-related genes in blood, sputum, saliva, feces, and urine and use them in various cancer treatments (Esteller, M. et al., Cancer Res., 59:67). , 1999; Sanchez-Cespedez, M. et al., Cancer Res., 60: 892, 2000; Ahlquist, DA et al., Gastroenterol., 119: 1219, 2000).
  • the present inventors have hypermethylated HOXA9, ISL1 and ALDH1A3 genes that are specifically methylated in bladder cancer cells through microarray analysis from non-muscle Invasive Bladder Cancer (NMIBC) tissue.
  • NMIBC non-muscle Invasive Bladder Cancer
  • the present invention relates to novel uses of specific genes HOXA9, ISL1 and ALDH1A3,
  • An object of the present invention is to provide a composition for markers for the diagnosis of bladder cancer, containing one or more of the above genes.
  • Another object of the present invention to provide a variety of uses for the diagnosis of bladder cancer and bladder cancer prognosis of the genes.
  • Still another object of the present invention is to provide a method for screening a substance having a therapeutic function of bladder cancer using the genes.
  • the present invention provides a biomarker of one or more genes selected from the group consisting of HOXA9, ISL1 and ALDH1A3 and a composition for markers for bladder cancer diagnosis containing them.
  • a biomarker of one or more genes selected from the group consisting of HOXA9, ISL1 and ALDH1A3 and a composition for markers for bladder cancer diagnosis containing them.
  • NMIBC non-muscle invasive bladder cancer
  • the genes are hypermethylated in bladder cancer and their expression is reduced, bladder cancer can be diagnosed. If possible, the genes are preferably used in a combination of two or more, and the more genes used in combination, the more preferable. Most preferably, they are used in combination of all three genes.
  • the diagnosis of bladder cancer according to the present invention may also include the diagnosis of bladder cancer prognosis, which may include the progression and recurrence of bladder cancer, in particular, in relation to the combination of genes, Is the combination of HOXA9 and ISL1, and in the case of relapse is most preferably used as a combination of HOXA9, ISL1 and ALDH1A3.
  • the present invention provides a composition for diagnosing bladder cancer, in one embodiment, comprising an agent for measuring the expression level of one or more genes selected from the group consisting of HOXA9, ISL1 and ALDH1A3.
  • Determining the expression level of the gene includes measuring the level of methylation, mRNA or protein, most preferably measuring the methylation level of the gene.
  • methylation level is known PCR, methylation specific PCR, real time methylation specific PCR, PCR using methylated DNA specific binding protein, quantitative PCR, pyro sequencing and Methods such as bisulfite sequencing can be used.
  • Agents for measuring the level of gene mRNA may comprise primers that specifically bind to one or more genes selected from the group consisting of HOXA9, ISL1 and ALDH1A3, and agents for measuring the levels of the proteins may be HOXA9, ISL1 and It may comprise an antibody specific for one or more proteins selected from the group consisting of ALDH1A3.
  • the present invention provides a kit for diagnosing bladder cancer prognosis comprising the diagnostic composition.
  • the kit may be an RT-PCR kit, a DNA chip kit or a protein chip kit.
  • the present invention provides a method for providing information for diagnosing the prognosis of non-muscular invasive bladder cancer, including:
  • the genes are preferably used in a combination of two or more, and the sample may be selected from the group consisting of tissue, cells, blood, serum, plasma, saliva and urine.
  • the present invention utilizes the gene function of the biomarker, and provides a method for screening a material for treating bladder cancer, in particular, non-invasive (superficial) bladder cancer, comprising the following steps.
  • the genes are preferably used in combination of two or more.
  • the present invention provides a variety of uses based on the novel function of HOXA9, ISL1 and ALDH1A3 genes as a prognostic diagnostic factor for bladder cancer, most preferably Non-muscle Invasive Bladder Cancer (NMIBC).
  • NMIBC Non-muscle Invasive Bladder Cancer
  • the present invention relates to a novel function of a particular gene, and has the effect of providing a composition and method for diagnosing the prognosis of bladder cancer, especially non-muscle invasive bladder cancer (NMIBC). .
  • the present invention may also provide a method for screening a therapeutic agent for bladder cancer by screening for substances that inhibit hypermethylation of the HOXA9, ISL1 and ALDH1A3 genes.
  • the present invention relates to the gene function of HOXA9, ISL1 and ALDH1A3 in bladder cancer, and may be usefully used for early diagnosis and treatment of bladder cancer.
  • Figure 1 schematically shows the experimental design and strategy for the present embodiment.
  • FIG. 4-10 are graphs showing Kaplan-Meier curves predicting the likelihood of relapse and progression according to methylation status in NMIBC patients [HOXA9 (FIG. 4), ISL1 (FIG. 5), ALDH1A3 (FIG. 6), And M score (FIG. 7); And ISL1 (FIG. 8), ALDH1A3 (FIG. 9), and M score (FIG. 10) for progression]
  • Diagnosis means identifying the presence or characteristic of a pathological condition. For the purposes of the present invention, the diagnosis is to predict or confirm the prognosis of bladder cancer. Especially, it is useful for the diagnosis of non-muscle invasive bladder cancer (NMIBC) prognosis.
  • NMIBC non-muscle invasive bladder cancer
  • “Diagnostic markers or diagnostic markers are substances that can differentiate bladder cancer cells from normal cells. Polypeptides or nucleic acids (e.g. mRNA, etc.) show an increased pattern in cells with bladder cancer compared to normal cells, Organic biomolecules such as lipids, glycolipids, glycoproteins, sugars (monosaccharides, disaccharides, polysaccharides, etc.), etc.
  • bladder cancer prognostic markers are hypermethylated in bladder cancer tissue with HOXA9, ISL1 and ALDH1A3. Are genes with reduced expression.
  • Prognosis means the prediction of the course and outcome of a disease, and the present invention encompasses the prediction of the recurrence progression of bladder cancer. Therefore, the indicators that can accurately predict the recurrence and progression of bladder cancer is very important, and factors that can predict the response of treatment while complementing clinical indicators such as tissue differentiation and staging, the genes of the present invention HOXA9, ISL1 and Since ALDH1A3 functions as an indicator, it can be used as a prognostic factor for bladder cancer. That is, the expression characteristics of these genes can be used as a prognostic indicator (diagnosis marker) useful for predicting the degree of differentiation, stage, and progression of bladder cancer.
  • Cancer refers to or describes the physiological state of a mammal, which is generally characterized by unregulated cell growth.
  • cancer include, but are not limited to, carcinoma, lymphoma, leukemia, blastoma and sarcoma.
  • Subject or “patient” means any single individual in need of treatment, including humans, cattle, dogs, guinea pigs, rabbits, chickens, insects, and the like. Also included are any subjects who participated in clinical research trials showing no disease clinical findings or subjects who participated in epidemiologic studies or who used as controls.
  • tissue or cell sample means a collection of similar cells obtained from a tissue of a subject or patient.
  • Sources of tissue or cell samples may include solid tissue from fresh, frozen and / or preserved organ or tissue samples or biopsies or aspirates; Blood or any blood component; Cells at any time of pregnancy or development in the subject. Tissue samples may also be primary or cultured cells or cell lines.
  • Nucleic acid is meant to include any DNA or RNA, eg, chromosomes, mitochondria, viruses, and / or bacterial nucleic acids present in tissue samples. One or both strands of a double stranded nucleic acid molecule and any fragment or portion of an intact nucleic acid molecule.
  • the nucleic acid used in the present invention is preferably a CpG-containing nucleic acid such as a CpG island.
  • Gene means any nucleic acid sequence or portion thereof that has a functional role in protein coding or transcription or in the regulation of other gene expression.
  • the gene may consist of any nucleic acid encoding a functional protein or only a portion of a nucleic acid encoding or expressing a protein.
  • Nucleic acid sequences may include gene abnormalities in exons, introns, initiation or termination regions, promoter sequences, other regulatory sequences, or unique sequences adjacent to genes.
  • gene expression generally refers to a cellular process in which a biologically active polypeptide is produced from a DNA sequence and exhibits biological activity in a cell.
  • gene expression includes not only transcriptional and translational processes, but also posttranscriptional and posttranslational processes that can affect the biological activity of a gene or gene product.
  • the processes include, but are not limited to, RNA synthesis, processing and transport, as well as post-translational modifications of polypeptide synthesis, transport and polypeptide.
  • aspects of gene expression include all cases of methylation of gene promoter, mRNA expression and protein expression.
  • a “coding region” or “coding sequence” refers to a nucleic acid sequence, complement thereof, or portion thereof that encodes a particular gene product or fragment thereof that requires expression, depending on the conventional base pair and codon usage relationship. Coding sequences include exons in genomic DNA or immature primary RNA transcripts that are linked together by a cell's biochemical machinery to provide mature mRNA. Antisense strands are complements of the nucleic acids, and coding sequences can be estimated from them. The coding sequence is placed in a relationship with transcriptional regulatory elements and translation initiation and termination codons such that transcripts of the appropriate length are produced and translated in the appropriate reading frame to produce the desired functional product.
  • An “primer” is an oligonucleotide sequence that hybridizes to complementary RNA or DNA target polynucleotides and functions as a starting point for the stepwise synthesis of polynucleotides from mononucleotides, for example by the action of nucleotidyltransferases that occur in polymerase chain reactions. Means.
  • a “protein” is also to include fragments, analogs and derivatives of a protein that possess essentially the same biological activity or function as the reference protein.
  • label or “label” is meant a compound or composition that directly or indirectly facilitates the detection of a reagent conjugated to, fused, conjugated or fused to a reagent, eg, a nucleic acid probe or antibody.
  • the label may itself be detected (eg, a radioisotope label or a fluorescent label) or, in the case of an enzyme label, may catalyze the chemical modification of the detectable substrate compound or composition.
  • down-regulation refers to a significant decrease in the expression level of a particular gene into mRNA or protein by intracellular transcription or translation compared to normal tissue cells. it means.
  • Antibody is used in its broadest sense and specifically refers to intact monoclonal (monoclonal) antibodies, polyclonal antibodies, multispecific antibodies (eg bispecific antibodies) formed from at least two intact antibodies and Antibody fragments that exhibit the desired biological activity.
  • Epigenetics refers to changes in gene expression that are inherited by offspring without alteration of DNA sequences.
  • abnormal genetic information due to changes in four nucleotide sequences (loss, substitution, amplification, etc.) accumulate in tumorigen genes or tumor suppressor genes, and their function is amplified or lost, affecting cancer development. But this alone has not been enough to explain the development, growth, and metastasis of cancer.
  • epidemiology that regulates the expression of genes without mutations is developing into a new field of cancer-related research. Epigenetic changes occur through processes such as DNA methylation, histone modification, and genomic imprinting.
  • Treatment means an approach to obtain beneficial or desirable clinical results.
  • beneficial or desirable clinical outcomes include, but are not limited to, alleviation of symptoms, reduction of disease range, stabilization of disease state (ie, not worsening), delay or slowing of disease progression, disease state Improvement or temporary mitigation and alleviation (partially or wholly), detectable or not detected.
  • Treatment may also mean increasing survival compared to expected survival when untreated. Treatment refers to both therapeutic treatment and prophylactic or preventive measures. Such treatments include the treatments required for the disorders that have already occurred as well as the disorders to be prevented. "Palliating" a disease may reduce the extent of the disease state and / or undesirable clinical signs and / or slow or lengthen the time course of progression as compared to untreated treatment. It means losing.
  • “About” means 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4 for reference quantities, levels, values, numbers, frequencies, percentages, dimensions, sizes, quantities, weights, or lengths. , Amount, level, value, number, frequency, percentage, dimension, size, amount, weight or length, varying by about 3, 2 or 1%.
  • the disease to be diagnosed in the present invention is a disease associated with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC).
  • NMIBC non-muscle invasive bladder cancer
  • Bladder cancer is the most frequent urinary tract tumor in Korea, and the mechanism and progression of bladder cancer are known to occur through various causes and stages. Recent studies on chromosomes and genetic abnormalities and the occurrence, recurrence and progression of bladder cancer There are many studies on prognostic factors that can predict.
  • Bladder cancer can be divided into superficial and invasive cancers at the time of initial diagnosis and appears superficial in about 75% of patients. Superficial tumors are more common, with about 30% of the recurrent superficial tumors showing higher malignancy or stage progression, and at 10%, the involvement into the muscle layer.1
  • For low malignant Ta lesions Relapses in 50-70%, progression to invasive bladder cancer in about 5%, high malignant T1 lesions relapse in more than 80% and progress to invasive bladder cancer in 50% of patients within 3 years.
  • Factors recognized to affect the progression of these tumors include bladder cancer found in T1 stage and G3 malignancy (T1G3), multiple epithelial cancer, high recurrence rate, residual tumor after bladder BCG therapy, and expression of p53 gene. Reported.
  • bladder extraction is known as a standard treatment.
  • the prognosis after invasive bladder cancer is T stage, N stage, lymph node density, malignancy, tumor size, number, type, lymph node / vascular involvement, and urinary tract epithelium. It is known to be related to the state of. Eighty to ninety percent of invasive bladder cancers are primary invasive bladder cancers without a history of previous superficial bladder cancers, but about 15% of those have previously progressed from superficial bladder cancers to invasive bladder cancers. There were also cases of primary bladder cancer diagnosed as invasive bladder cancer at the first diagnosis and superficial bladder cancer at the first diagnosis, but recurred and advanced to invasive bladder cancer (advanced invasive cancer).
  • HOXA9, ISL1 and ALDH1A3 genes are hypermethylated in Bladder Cancer cancer tissues. That is, the expression relationship between bladder cancer and specific genes was first identified.
  • the present invention relates to the use of one or more genes selected from HOXA9, ISL1 and ALDH1A3 as a diagnostic marker for bladder cancer prognosis, and to predict and diagnose the bladder cancer prognosis by confirming whether the gene is hypermethylated and thus reduced expression. Can be. In particular, it is very useful for prognostic diagnosis of non-muscle Invasive Bladder Cancer (NMIBC).
  • NMIBC non-muscle Invasive Bladder Cancer
  • Prognosis of the bladder cancer includes recurrence and progression.
  • recurrence is defined as the relapse of primary NMIBC at lower or equivalent pathological stage, and progression is defined as muscle infiltration (TNM stage T2 or higher) or metastatic disease.
  • the present invention relates to the use of at least one gene selected from HOXA9, ISL1 and ALDH1A3 as a prognostic diagnostic marker of bladder cancer and bladder cancer in one aspect.
  • significant diagnostic markers mean markers of high reliability such that the results obtained by diagnosis are accurate, have high validity, and show consistent results in repeated measurements.
  • Bladder cancer prognosis diagnostic marker of the present invention shows the same result in repeated experiments with genes whose expression changes by direct or indirect factors with the onset of bladder cancer, and the difference in expression level is very large when compared with the control group, resulting in incorrect results. Highly reliable markers with little probability. Therefore, the result of diagnosis based on the result obtained by measuring the expression level of the significant diagnostic marker of the present invention can be reasonably reliable.
  • genes of the present invention are characterized in that they are hypermethylated and downregulated in bladder cancer tissues.
  • bladder cancer can be predicted through methylation and / or downregulation of HOXA9, ISL1 and ALDH1A3 genes.
  • the present invention can be used individually as a diagnostic or predictive marker, or in combination with several marker genes in the form of a panel display, where several marker genes are reliable through an overall expression pattern or a list of methylated genes. And to improve the efficiency.
  • the genes identified in the present invention can be used individually or as a set of genes in which the genes mentioned in this example are combined. Alternatively, genes can be ranked, weighted, and selected for the level of likelihood of developing cancer, depending on the number and importance of the genes methylated together.
  • it can be determined by a combination of two or more of the genes, most preferably a combination of all three genes.
  • the progression of the bladder cancer can be measured by the combination of HOXA9 and ISL1 in the case of progression, and by the combination of HOXA9, ISL1 and ALDH1A3 in the case of recurrence.
  • the present invention relates to a composition for diagnosing bladder cancer prognosis comprising an agent for measuring the expression level of one or more genes selected from HOXA9, ISL1 and ALDH1A3.
  • the 'gene expression level measurement' includes both measuring the level of methylation, mRNA or protein thereof. Most preferably the methylation level is measured.
  • DNA methylation refers to the binding of methyl groups (CH3) to the 5 carbon sites of CpG by DNA methyl transferase (DNMT), which occurs in the promoter CpG islands, and this DNA methylation is responsible for cell cycle or apoptosis. Regulate, repair DNA, and are involved in cell adhesion and intercellular interaction.
  • DNMT DNA methyl transferase
  • CpG islands are sites of 0.2-3kb in length with a C + G content of at least 50% and a CpG ratio of at least 3.75%. There are about 45,000 CpG islands in the human genome, most of which are found at promoter sites that regulate gene expression. Indeed, the CpG islands are found in promoters of housekeeping genes, about 50% of human genes (Cross, S. and Bird, A., Curr. Opin. Gene Develop., 5: 309, 1995). . The CpG is a site where most epigenetic changes occur frequently in mammalian cells.
  • HOXA9, ISL1 and / or ALDH1A3 promoter CpG islands of the invention are methylated, such methylation inhibits expression and function of the gene in the same way as mutations in the coding sequence, thereby developing, recurring and progressing cancer. This will be facilitated.
  • a method for detecting whether the gene is promoter methylated may include the following steps:
  • step (c) determining whether the promoter is methylated based on the presence or absence of the amplified product produced in step (b).
  • the measurement of the DNA methylation level can use various known methods.
  • the methylation measurement method may be PCR, methylation specific PCR, real time methylation specific PCR, PCR using methylated DNA specific binding protein, quantitative PCR, pyrosequencing and vi It may be characterized in that it is selected from the group consisting of sulfite sequencing.
  • PCR primers corresponding to the sites where the 5'-CpG-3 'nucleotide sequence exists were prepared for the converted nucleotide sequence after bisulfite treatment.
  • PCR primers corresponding to methylation and two types of primers corresponding to unmethylated were prepared.
  • Real-time methylation-specific PCR converts the methylation-specific PCR method into a real-time measurement method. After treating bisulfite on genomic DNA, a PCR primer corresponding to methylation is designed and real-time PCR is performed using these primers. It is. At this time, there are two methods of detection using a TaqMan probe complementary to the amplified base sequence, and two methods of detection using Sybergreen. Thus, real-time methylation specific PCR can selectively quantitate only methylated DNA.
  • a standard curve may be prepared using an in vitro methylated DNA sample, and the standardization may be quantitatively analyzed by amplifying a gene without a 5'-CpG-3 'sequence in a nucleotide sequence into a negative control group.
  • the pyro sequencing method is a method of converting the bisulfite sequencing method into quantitative real-time sequencing.
  • genomic DNA was converted by bisulfite treatment, and PCR primers corresponding to sites without the 5'-CpG-3 'sequence were prepared.
  • the genomic DNA was treated with bisulfite, amplified with the PCR primers, and then subjected to real-time sequencing using the sequencing primers. Quantitative analysis of the amount of cytosine and thymine at the 5'-CpG-3 'site can indicate the degree of methylation as the methylation index.
  • methylated DNA-specific binding proteins when a protein that specifically binds to methylated DNA is mixed with DNA, only methylated DNA can be selectively separated because the protein specifically binds to methylated DNA. . After genomic DNA was mixed with methylated DNA specific binding proteins, only methylated DNA was selectively isolated. After amplifying these separated DNA using a PCR primer corresponding to the promoter site, it can be determined whether or not methylation by agarose electrophoresis.
  • methylation can also be determined by quantitative PCR.
  • Methods for labeling DNA separated by methylated DNA-specific binding proteins can be labeled with a fluorescent dye and hybridized to DNA chips having complementary probes to measure methylation. Can be.
  • detecting nucleic acids containing methylated CpG include contacting a sample containing nucleic acid with an agent that modifies unmethylated cytosine and amplifying the CpG-containing nucleic acid of the sample using CpG-specific oligonucleotide primers. It includes.
  • the oligonucleotide primer may be characterized by detecting the methylated nucleic acid by distinguishing the modified methylated and unmethylated nucleic acid.
  • the amplification step is optional and desirable but not necessary.
  • the method relies on a PCR reaction that distinguishes between modified (eg, chemically modified) methylated and unmethylated DNA. Such methods are disclosed in US Pat. No. 5,786,146, which is described in connection with bisulfite sequencing for the detection of methylated nucleic acids.
  • Measurement of mRNA expression level is to measure the amount of mRNA in the process of confirming the presence and expression of mRNA of the marker genes in a biological sample to diagnose bladder cancer.
  • RT-PCR reverse transcriptase
  • RT competitive reverse transcriptase
  • RPA RNase protection assay
  • the primers used may initiate DNA synthesis in the presence of reagents for polymerization (ie, DNA polymerase or reverse transcriptase) and four different nucleoside triphosphates in appropriate buffers and temperatures.
  • Primers of the invention are sense and antisense nucleic acids having 7 to 50 nucleotide sequences as primers specific for each marker gene. Primers can incorporate additional features that do not change the basic properties of the primers that serve as a starting point for DNA synthesis.
  • the primers can be chemically synthesized using other well known methods and can be modified using many means known in the art.
  • the nucleic acid sequence can also be modified with a label that can provide a detectable signal directly or indirectly. Examples of labels include radioisotopes, fluorescent molecules, biotin, and the like.
  • a bladder cancer diagnostic marker composition comprising a primer sequence specific for one or more genes selected from HOXA9, ISL1 and ALDH1A3.
  • the down-regulation by measuring the mRNA expression level of the genes may provide a use for diagnosing the prognosis of the bladder cancer.
  • protein expression level measurement is a process of confirming the presence and expression level of a protein expressed from a bladder cancer marker gene in a biological sample in order to diagnose bladder cancer.
  • the antibody specifically binds to the protein of the gene. You can check the amount of protein using.
  • an antibody means a specific protein molecule directed against an antigenic site.
  • an antibody refers to an antibody that specifically binds to a marker protein and includes all polyclonal antibodies, monoclonal antibodies and recombinant antibodies.
  • Analytical methods for this purpose include Western blot, ELISA (enzyme linked immunosorbent assay, ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket Immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, Fluorescence Activated Cell Sorter (FACS), protein chip, etc., but are not limited to these. .
  • the present invention can provide a bladder cancer diagnostic marker composition comprising an antibody specific for at least one protein selected from HOXA9, ISL1 and ALDH1A3.
  • a bladder cancer diagnostic marker composition comprising an antibody specific for at least one protein selected from HOXA9, ISL1 and ALDH1A3.
  • tissue or cell samples from mammals can be used. Samples can be obtained by a variety of procedures known in the art, including but not limited to surgical excision, aspiration or biopsy. The tissue may be fresh or frozen.
  • Tissue samples can be fixed (ie preserved) by conventional methods.
  • fixative may be selected depending on the purpose for which the sample is histologically stained or otherwise analyzed.
  • length of fixation is determined by the size of the tissue sample and the fixative used.
  • the method further includes a protocol for examining methylation levels, mRNA or protein expression in tissue or cell samples.
  • a protocol for examining methylation levels, mRNA or protein expression in tissue or cell samples As described above, methods for evaluating methylation, mRNA, protein in cells are well known in the art.
  • the method may also include a protocol for investigating or detecting methylation and mRNA in tissue or cell samples by microarray technology.
  • Microarray methods can simultaneously study the RNA expression of thousands or even tens of thousands of genes in a tumor, making it possible to more effectively gain comprehensive insight into the molecular basis of human disease. It can also be used to assess gene expression patterns, clinical outcomes and responses to chemotherapy in tumor classification.
  • the prognostic diagnosis of bladder cancer is possible by measuring the expression of one or more genes selected from HOXA9, ISL1 and ALDH1A3 by the above protocol using a sample.
  • the gene is preferably measured in many different combinations.
  • Probes can be labeled for detection and can be labeled, for example, with radioisotopes, fluorescent compounds, bioluminescent compounds, chemiluminescent compounds, metal chelates or enzymes. Proper labeling of such probes is a technique well known in the art and can be carried out by conventional methods.
  • the present invention relates to a kit for diagnosing human bladder cancer prognosis.
  • the kit is used to determine the prognosis of bladder cancer, preferably Non-muscle Invasive Bladder Cancer (NMIBC) by analyzing the expression of one or more genes selected from HOXA9, ISL1 and ALDH1A3. This can be done in two ways: genetic analysis and immunoassay.
  • NMIBC Non-muscle Invasive Bladder Cancer
  • the kit may comprise, for example, a primer or probe that specifically binds one or more gene sequences selected from HOXA9, ISL1 and ALDH1A3; Or an antibody that specifically binds one or more proteins selected from HOXA9, ISL1, and ALDH1A3.
  • the kit of the present invention may optionally contain reagents necessary for PCR amplification, such as buffers, DNA polymerases (eg, Thermus aquaticus (Taq), Thermus). thermophilus (Tth), Thermus filiformis, Thermis flavus, Thermococcus literalis or thermally stable DNA polymerase obtained from Pyrococcus furiosus (Pfu)), DNA polymerase cofactors and dNTPs.
  • the kit for diagnosing human bladder cancer of the present invention is applied to an immunoassay
  • the kit of the present invention may optionally include a secondary antibody and a substrate of a label.
  • Kits of the invention can be prepared in a number of separate packaging or compartments containing the reagent components described above.
  • another aspect of the present invention provides a bladder cancer diagnostic kit comprising the composition for diagnosing bladder cancer according to the present invention.
  • the diagnostic kit may further comprise one or more other component compositions, solutions or devices suitable for the assay method.
  • kits of the invention comprise a compartmentalized carrier means for holding a sample, a first container containing an agent that sensitively cleaves unmethylated cytosine, a second container containing a primer for amplifying CpG containing nucleic acid and a truncated or It may include one or more containers including a third container containing means for detecting the presence of the uncleaved nucleic acid.
  • the present invention provides a method for diagnosing bladder cancer or a method for providing information for diagnosing bladder cancer, the method comprising measuring expression levels of at least one gene selected from HOXA9, ISL1, and ALDH1A3 based on the findings.
  • the 'gene expression level measurement' includes all of the levels of methylation, mRNA or protein thereof, methylation and / or downregulation of the HOXA9, ISL1 and ALDH1A3 genes may be used to predict information on the prognosis of bladder cancer. Can be.
  • the combination of HOXA9 and ISL1 can be used to obtain information about the case of progression during the prognosis of bladder cancer and the case of recurrence with the combination of HOXA9, ISL1 and ALDH1A3.
  • the expression of the HOXA9, ISL1 and ALDH1A3 gene is characterized in that it is an indicator for bladder cancer.
  • the method for diagnosing bladder cancer prognosis relates to investigating the expression of specific markers according to non-muscle Invasive Bladder Cancer (NMIBC), in particular the method disclosed herein It may provide a convenient, efficient and cost effective means for obtaining useful data and information when evaluating appropriate or effective therapies.
  • NMIBC non-muscle Invasive Bladder Cancer
  • the present invention relates to a method for screening a substance for treating bladder cancer, which inhibits methylation of HOXA9, ISL1, and ALDH1A3, based on the above-described fact.
  • the method is an embodiment
  • the present invention extends to a genetic approach to up-regulation or down-regulation of expression of genes involved in methylation of HOXA9, ISL1 and ALDH1A3.
  • the present invention shows increased methylation and decreased expression profile of at least one gene selected from HOXA9, ISL1 and ALDH1A3 in patients with bladder cancer, preferably Non-muscle Invasive Bladder Cancer (NMIBC).
  • NMIBC Non-muscle Invasive Bladder Cancer
  • NMIBC samples were obtained from 181 primary NMIBC patients who underwent transurethral resection (TUR) between 1995 and 2010 for histologically-diagnosed transitional cell carcinomas.
  • NMIBC sample was identified by pathological analysis of the tissue sample portion (ie, sections from TUR samples were snap-frozen in liquid nitrogen and stored at -80 ° C). Samples used in the experiment were provided by Chungbuk National University Hospital. The collection and analysis of all samples was approved by the Institutional Review Board of Chungbuk National University Hospital and agreed with each patient.
  • Tumors were staged according to the 2002 TNM classification and the 1973 WHO grading system. If the bladder cancer sample did not contain adequate muscle or high levels of tumor were detected, a second TUR was performed 2-4 weeks after the first resection. Medium- or high-risk NMIBC patients received one cycle of urinary bladder therapy. Each patient was followed up and managed according to standard recommendations.
  • Recurrence was defined as a relapse of primary NMIBC at lower or equivalent pathological stage, and progression was defined as muscle infiltration (TNM stage T2 or higher) or metastatic disease.
  • ⁇ values represent quantitative measurements of DNA methylation levels of specific CpG islands from 0 (completely unmethylated) to 1 (complete methylation).
  • DNA methylation sites of NMIBC-specific hypermethylated CpG sites were analyzed by PSQ using PyroMark Q96 ID (Qiagen, Valencia, CA).
  • PSQ primers were designed to include CpG sites analyzed on Illumina Infinium array.
  • the primer sequences and amplification conditions are listed in Table 1 below.
  • Primers were designed using NCBI Reference Sequences build version 36.1. PCR reactions included 0.01 ⁇ M primers, Bioneer Taq (Bioneer, Daejeon, Korea), and 20 ng bisulfite-treated DNA. Thermal cycling parameters are as follows: denaturation at 94 ° C. for 5 minutes; 45 cycles at 94 ° C. for 30 seconds, 52 ° C. for 30 seconds, and 72 ° C. for 30 seconds; And final elongation at 72 ° C. for 5 minutes.
  • DNA methylation and gene expression profile data were normalized using displacement normalization in the R language environment (version 2.10.0, available at http://www.r-project.org/). Specific analytical methods are described in Mol Cancer. 2010; 9: 3; J Clin Oncol. 2010; 28: 2660-7; And Clin Cancer Res. 2011; 17: 4523-30, and the like.
  • ROC Receiver operating characteristic
  • the methylation score (M score) of each patient was calculated as the sum of the methylation levels of the selected genes increased by the regression coefficient derived from Cox regression analysis used to assess the predictable value of each gene.
  • M score the prognostic values of methylation sites are individually assessed and well-known clinicopathology (gender, age, tumor size, tumor count, urinary tract). Intra-bladder treatment, extent and stage).
  • relapse-free survival and progression-free survival were 47.2 ⁇ 40.4 months (median 35.8, range 6.1 to 183.3) and 61.1 ⁇ 41.7 months (median 50.9, range 6.6 to 183.3), respectively, among NMIBC patients.
  • DNA methylation-induced gene silencing To confirm DNA methylation-induced gene silencing, the correlation between DNA methylation and gene expression levels was calculated using microarray expression data and matched PSQ values from 89 subjects.
  • methylation levels were observed in terms of known prognostic factors such as tumor number, tumor size and tumor severity and stage.
  • b P-values are calculated using ANOVA trend analysis test.
  • methylation values of each gene were divided into two by the optimal cut-off point based on the ROC curve analysis.
  • M scores for relapse HXA9, ISL1 and, ALDH1A3 and progression (ISL1 and ALDH1A3) were calculated, respectively.
  • the patients were then classified into two groups accordingly.
  • HR risk ratios
  • HR includes clinical pathologic factors [gender, age, tumor size ( ⁇ 3 cm vs. ⁇ 3 cm), single vs. multiple, urinary bladder therapy (no vs. yes), tumor extent. (G1 vs. G2 vs. G3), and step T (Ta vs. T1)].
  • HR is determined by each gene methylation status and clinicopathological factors.
  • Kaplan-Meier evaluation confirmed a significant difference in time versus relapse or progression with methylation status (log-rank test, P ⁇ 0.05).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/KR2013/007305 2012-08-14 2013-08-14 Marqueur de pronostic et de diagnostic du cancer de la vessie Ceased WO2014027831A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0088882 2012-08-14
KR1020120088882A KR101557183B1 (ko) 2012-08-14 2012-08-14 방광암 예후 진단 마커

Publications (1)

Publication Number Publication Date
WO2014027831A1 true WO2014027831A1 (fr) 2014-02-20

Family

ID=50268321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/007305 Ceased WO2014027831A1 (fr) 2012-08-14 2013-08-14 Marqueur de pronostic et de diagnostic du cancer de la vessie

Country Status (2)

Country Link
KR (1) KR101557183B1 (fr)
WO (1) WO2014027831A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107475369A (zh) * 2017-07-07 2017-12-15 南方医科大学 Hoxa9基因在制备治疗皮肤鳞状细胞癌药物中的应用
CN109797221A (zh) * 2019-03-13 2019-05-24 上海市第十人民医院 一种用于对肌层浸润性膀胱癌进行分子分型和/或预后预测的生物标记物组合及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101750146B1 (ko) * 2014-12-30 2017-06-23 충북대학교 산학협력단 방광암 예후 진단 마커로서 ｒｓｐｈ９의 용도
KR102029775B1 (ko) 2018-01-23 2019-10-08 충북대학교 산학협력단 비근침윤성 방광암 진단용 바이오마커 및 이의 용도
KR102171774B1 (ko) 2018-06-04 2020-10-29 울산대학교 산학협력단 인산화된 tfcp2l1을 포함하는 고형암 예후 예측용 바이오마커 조성물 및 이의 용도
KR102346864B1 (ko) 2019-07-24 2022-01-04 한국전자기술연구원 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법
KR102235718B1 (ko) 2019-08-01 2021-04-05 한국전자기술연구원 방광암 진단 또는 예후 분석용 바이오마커 조성물, 키트 및 이를 이용한 진단 방법
KR102605676B1 (ko) 2020-02-20 2023-11-27 이원다이애그노믹스(주) 핵산의 메틸화 차이를 이용한 마커 선별방법, 메틸 또는 탈메틸 마커 및 이 마커를 이용한 진단방법
KR102658209B1 (ko) 2021-10-05 2024-04-18 재단법인 아산사회복지재단 Cdk 억제제 및 id2 활성화제를 포함하는 방광암의 예방 또는 치료용 약학 조성물
KR102701683B1 (ko) 2022-10-31 2024-09-02 주식회사 지씨지놈 폐암 진단용 dna 메틸화 마커 및 이의 용도
KR102701682B1 (ko) 2022-10-31 2024-09-02 주식회사 지씨지놈 간암 진단용 dna 메틸화 마커 및 이의 용도
EP4628597A1 (fr) 2022-11-29 2025-10-08 GC Genome Corporation Marqueurs de méthylation de l'adn pour le diagnostic du cancer de l'oesophage et du cancer de l'estomac et leur utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529630A (ja) * 2001-03-01 2004-09-30 エピゲノミクス アーゲー 診断および治療目的の遺伝子パネルを遺伝子の発現およびメチル化状態に基づいて開発する方法
US20090023142A1 (en) * 2005-02-18 2009-01-22 Sloan-Kettering Institute For Cancer Research Methods for Detecting Minimum Residual Disease
WO2010123354A2 (fr) * 2009-04-20 2010-10-28 Erasmus University Medical Center Rotterdam Méthode de diagnostic du cancer de la vessie
EP2481814A2 (fr) * 2003-06-09 2012-08-01 The Regents of the University of Michigan Compositions et procédés de diagnostic et de traitement des cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529630A (ja) * 2001-03-01 2004-09-30 エピゲノミクス アーゲー 診断および治療目的の遺伝子パネルを遺伝子の発現およびメチル化状態に基づいて開発する方法
EP2481814A2 (fr) * 2003-06-09 2012-08-01 The Regents of the University of Michigan Compositions et procédés de diagnostic et de traitement des cancers
US20090023142A1 (en) * 2005-02-18 2009-01-22 Sloan-Kettering Institute For Cancer Research Methods for Detecting Minimum Residual Disease
WO2010123354A2 (fr) * 2009-04-20 2010-10-28 Erasmus University Medical Center Rotterdam Méthode de diagnostic du cancer de la vessie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REINERT THOMAS ET AL.: "COMPREHENSIVE GENOME METHYLATION ANALYSIS IN BLADDER CANCER IDENTIFICATION AND VALIDATION OF NOVEL METHYLATED GENES AND APPLICATION OF THESE AS URINARY TUMOR MARKERS", CLINICAL CANCER RESEARCH, vol. 17, no. 17, pages 5582 - 5592 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107475369A (zh) * 2017-07-07 2017-12-15 南方医科大学 Hoxa9基因在制备治疗皮肤鳞状细胞癌药物中的应用
CN107475369B (zh) * 2017-07-07 2021-05-04 南方医科大学 Hoxa9基因在制备治疗皮肤鳞状细胞癌药物中的应用
CN109797221A (zh) * 2019-03-13 2019-05-24 上海市第十人民医院 一种用于对肌层浸润性膀胱癌进行分子分型和/或预后预测的生物标记物组合及其应用

Also Published As

Publication number Publication date
KR20140022293A (ko) 2014-02-24
KR101557183B1 (ko) 2015-10-02

Similar Documents

Publication Publication Date Title
WO2014027831A1 (fr) Marqueur de pronostic et de diagnostic du cancer de la vessie
US11840739B2 (en) Gene composition for detecting cell proliferative abnormality or grading disease degree and use thereof
JP6141896B2 (ja) 選択された遺伝子のエピジェネティックな変化及び癌
WO2014073785A1 (fr) Procédé permettant de détecter les polypes gastriques et le cancer gastrique à l'aide d'un gène marqueur du polype gastrique et de la méthylation spécifique du cancer gastrique
WO2012081898A2 (fr) Marqueur destiné à établir un pronostic du cancer de l'estomac et procédé d'établissement d'un pronostic du cancer de l'estomac
JP6397762B2 (ja) がん被験体の予後を決定する方法及び核酸
WO2009113771A1 (fr) Méthode de dépistage du cancer du poumon au moyen de gènes marqueurs de méthylation spécifiques du cancer du poumon
US20140113286A1 (en) Epigenomic Markers of Cancer Metastasis
WO2015023146A1 (fr) Méthode de détection de lésions précancéreuses
CN101675171A (zh) 用basp1基因和/或srd5a2基因中的甲基化胞嘧啶检测肝癌、肝癌风险、肝癌复发风险、肝癌恶化和肝癌随时间进展的方法
JP2005204651A (ja) 乳房細胞増殖障害の患者の治療応答及び／又は生存期間の予測のための予後診断マーカー
Chan et al. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma
WO2021075797A2 (fr) Composition pour le diagnostic de cancer du foie à l'aide de modifications de la méthylation de cpg dans des gènes spécifiques et son utilisation
WO2012081928A2 (fr) Procédé pour la détection de la méthylation du gène gpm6a marqueur de méthylation spécifique au cancer des intestins en vue du diagnostic du cancer des intestins
WO2014168346A1 (fr) Méthode de dépistage du cancer de la vessie au moyen d'un gène marqueur épigénétique spécifique du cancer de la vessie
WO2021230663A1 (fr) Procédé de prédiction de pronostic de patients atteints d'un cancer du sein précoce
WO2016108403A1 (fr) Utilisation du gène rsph9 comme marqueur diagnostique/pronostique du cancer de la vessie
WO2013147330A1 (fr) Système de prédiction de pronostic du cancer gastrique avancé localement
WO2011122859A2 (fr) Composition permettant de prédire la récidive d'une tumeur cérébrale et les chances de survie et kit la contenant
WO2023234485A1 (fr) Biomarqueur pour prédire la probabilité de développer un cancer gastrique et son utilisation
WO2022075788A1 (fr) Composition pour diagnostiquer un cancer colorectal, un cancer rectal ou un adénome colorectal à l'aide d'un changement de méthylation cpg du gène linc01798, et son utilisation
US20090111120A1 (en) Methylation of genes as a predictor of polyp formation and recurrence
WO2024158203A1 (fr) Composition pour prédire le risque de développer un cancer du foie
WO2021206467A1 (fr) Composition pour diagnostiquer un cancer colorectal, un cancer rectal ou un adénome colorectal à l'aide d'un changement de méthylation cpg du gène glrb, et son utilisation
WO2011049322A2 (fr) Procédé de détection de la méthylation d'un gène de marqueur de méthylation spécifique de cancer du sein pour le diagnostic du cancer du sein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13879582

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13879582

Country of ref document: EP

Kind code of ref document: A1